Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale

Mary Hobart, Peter Zhang, Catherine Weiss, Stine Rasmussen Meehan, Hans Eriksson, Mary Hobart, Peter Zhang, Catherine Weiss, Stine Rasmussen Meehan, Hans Eriksson

Abstract

Background: Patients with major depressive disorder and inadequate response to antidepressant treatments may experience a prolonged loss of functioning. This post hoc analysis aimed to determine the effect of adjunctive brexpiprazole on functioning in such patients.

Methods: A pooled analysis of data from the 6-week, randomized, double-blind treatment phases of 6 studies of adjunctive brexpiprazole (2 and 3 mg/d in fixed-dose studies; 1-3 mg/d in flexible-dose studies) vs placebo in patients with major depressive disorder and inadequate response to antidepressant treatments (NCT01360645, NCT01360632, NCT02196506, NCT01727726, NCT00797966, NCT01052077). Functioning was measured by change in Sheehan Disability Scale score from baseline to week 6.

Results: Considering Sheehan Disability Scale mean score across all 6 studies (n = 2066 randomized), the least squares mean difference between antidepressant treatments + brexpiprazole and antidepressant treatments + placebo at week 6 was -0.40 (95% CI: -0.56, -0.23; P < .0001). Antidepressant treatments + brexpiprazole showed a greater benefit than antidepressant treatments + placebo on the social life (-0.45; -0.63, -0.27; P < .001) and family life (-0.50; -0.70, -0.31; P < .001) items but not on the work/studies item (-0.16; -0.38, 0.06; P = .16). Pooled analyses of just the (1) fixed-dose, (2) flexible-dose, and (3) Phase 3 studies showed the same pattern of benefits for antidepressant treatments + brexpiprazole.

Conclusions: Brexpiprazole, as adjunct to antidepressant treatments, improved functioning in patients with major depressive disorder and inadequate response to antidepressant treatments.

Keywords: Sheehan Disability Scale; adjunctive; brexpiprazole; depression; functioning.

© The Author(s) 2018. Published by Oxford University Press on behalf of CINP.

Figures

Figure 1.
Figure 1.
Estimated treatment effect for antidepressant treatment (ADT) + brexpiprazole: mean change in Sheehan Disability Scale (SDS) mean score from baseline to week 6 (efficacy populationa). Abbreviations: CI, confidence interval; LS, least squares; MMRM, mixed model for repeated measures. MMRM for Pyxis, Polaris, Sirius, and Delphinus; ANCOVA for Study 211 and Study 222; MMRM for pooled analyses. aPer target population, defined as patients who met criteria for consistent inadequate response throughout the prospective treatment phase. This definition was retrospectively applied to study 211 and study 222.
Figure 2.
Figure 2.
Mean change in Sheehan Disability Scale (SDS) mean and item scores from baseline to week 6, for all studies pooled (efficacy populationa). Abbreviations: ADT, antidepressant treatment; LS, least squares; MMRM, mixed model for repeated measures. ***P < .001 vs ADT + placebo; MMRM. aPer target population, defined as patients who met criteria for consistent inadequate response throughout the prospective treatment phase. This definition was retrospectively applied to study 211 and study 222. bThe following brexpiprazole dose groups were included in the pooled analysis: Pyxis and Sirius, 2 mg/d; Polaris, 3 mg/d; Delphinus, 2–3 mg/d; study 211, 1.5 ± 0.5 mg/d; study 222, 1–3 mg/d.

References

    1. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:843–853.
    1. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN (2009) Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14:197–206.
    1. Citrome L. (2010) Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 122:39–48.
    1. Fried EI, Nesse RM (2014) The impact of individual depressive symptoms on impairment of psychosocial functioning. PLoS One 9:e90311.
    1. Hobart M, Skuban A, Zhang P, Augustine C, Brewer C, Hefting N, Sanchez R, McQuade RD (2018a) A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder. J Clin Psychiatry 79:17m12058.
    1. Hobart M, Skuban A, Zhang P, Josiassen MK, Hefting N, Augustine C, Brewer C, Sanchez R, McQuade RD (2018b) Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. Curr Med Res Opin 34:633–642.
    1. Hobart M, Zhang P, Skuban A, Brewer C, Hefting N (2018c) Long-term safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder. Poster presented at: the Annual Meeting of the American Psychiatric Association; May 5–9; New York City, NY.
    1. Jha MK, Minhajuddin A, Greer TL, Carmody T, Rush AJ, Trivedi MH (2016) Early improvement in work productivity predicts future clinical course in depressed outpatients: findings from the CO-MED trial. Am J Psychiatry 173:1196–1204.
    1. Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T; ADMIRE Study Group (2013) Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Disord 151:899–905.
    1. Kessler RC. (2012) The costs of depression. Psychiatr Clin North Am 35:1–14.
    1. Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, Jin R, Merikangas KR, Wang PS (2006) Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry 163:1561–1568.
    1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS; National Comorbidity Survey Replication (2003) The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 289:3095–3105.
    1. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T (2014) Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:589–604.
    1. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:156–165.
    1. Mauskopf JA, Simon GE, Kalsekar A, Nimsch C, Dunayevich E, Cameron A (2009) Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety 26:83–97.
    1. McKnight PE, Kashdan TB (2009) The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev 29:243–259.
    1. Nelson JC, Zhang P, Skuban A, Hobart M, Weiss C, Weiller E, Thase ME (2016) Overview of short-term and long-term safety of brexpiprazole in patients with major depressive disorder and inadequate response to antidepressant treatment. Curr Psychiatry Rev 12:278–290.
    1. Rexulti® (brexpiprazole) tablets, for oral use (2018) Prescribing information Accessed August 20, 2018.
    1. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917.
    1. Saltiel PF, Silvershein DI (2015) Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat 11:875–888.
    1. Sheehan DV. (1983) The anxiety disease. New York, NY: Charles Scribner & Sons.
    1. Sheehan DV, Harnett-Sheehan K, Raj BA (1996) The measurement of disability. Int Clin Psychopharmacol 11:89–95.
    1. Sheehan KH, Sheehan DV (2008) Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 23:70–83.
    1. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013) Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 10:e1001403.
    1. Thase M, Fava M, Hobart M, Skuban A, Zhang P, McQuade RD, Carson WH, Sanchez R, Forbes RA (2011) Efficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: a phase II, randomized, placebo-controlled study. Neuropsychopharmacology 36:S302–S304.
    1. Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H (2015a) Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 76:1224–1231.
    1. Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H (2015b) Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 76:1232–1240.
    1. Thase ME, Zhang P, Skuban A, Hobart M, Weiss C, Weiller E, Nelson JC (2016) Efficacy of adjunctive brexpiprazole in patients with major depressive disorder: a clinical overview. Curr Psychiatry Rev 12:291–301.
    1. Trivedi MH, Morris DW, Wisniewski SR, Lesser I, Nierenberg AA, Daly E, Kurian BT, Gaynes BN, Balasubramani GK, Rush AJ (2013) Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry 170:633–641.
    1. Weiller E, Weiss C, Watling CP, Edge C, Hobart M, Eriksson H, Fava M (2018) Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies. Neuropsychiatr Dis Treat 14:103–115.
    1. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N (2006) Discordance between self-reported symptom severity and psychosocial functioning ratings in depressed outpatients: implications for how remission from depression should be defined. Psychiatry Res 141:185–191.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit